NYSE:CRLLife Sciences
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform
Charles River Laboratories International (NYSE:CRL) has entered into a partnership with MEDIPOST to support development and commercialization of cell therapies across Asia-Pacific and North America.
The company is supplying biologics and GMP testing services to MEDIPOST’s global pipeline of regenerative medicine products.
At the same time, Charles River introduced major upgrades to its digital pathology platform, adding AI-powered and fully digital workflows.
The new digital pathology...